Optiscan collaborates with Summit Biomedical Imaging for commercializing a drug/device combination.

Optiscan is pleased to announce that it has entered into a collaboration agreement with Summit Biomedical Imaging (SBI) for the purposes of discussions regarding commercialization of a drug/device combination for various clinical applications involving SBI’s PARPi-FL imaging agent and Optiscan’s FIVE2 (Viewnvivo) confocal endomicroscope. These applications include using PARPi-FL in the breast cancer tumour margin assessment trial currently being conducted by Optiscan.